At the heart of Smilow Cancer Hospital and Yale Cancer Center, our commitment to safety, compassionate care, and research excellence will always remain.
Yale Cancer Center
Your physicians and caregivers remain committed to you during the current COVID-19 pandemic. Please reach out if you have any questions about your upcoming appointment, scans, or tests. We have taken precautionary steps to ensure the health and safety of our patients and their families during their appointments and while receiving treatment. We are also reaching out to you virtually with support groups, integrative medicine opportunities, and other resources online. We are here for you! Learn More >>
Yale Cancer Center is one of only 51 Comprehensive Cancer Centers in the country designated by the National Cancer Institute. The significance of this designation has profound implications for those who choose Yale as the place where they will be cared for and receive treatment for their cancer.
In the fight against cancer, Yale has been at the forefront of understanding the fundamental mechanisms of cancer biology and in developing effective therapies for cancer treatment. Yale Cancer Center harnesses the resources of Yale School of Medicine and Yale New Haven Hospital to advance cancer research, prevention, and patient care, as well as community outreach and education.
Latest News
- May 18, 2022Source: WCBS 880 AM
Audio: Dr. Preston Sprenkle on Health & Well-being on WCBS 880AM
- May 16, 2022
Elevated Biomarkers Offer Early Indicator of Severe COVID-19, Study Says
- May 16, 2022
A Faster, Broader Pipeline for Phase I Clinical Trials Investigating Immunotherapies, Targeted Therapies
- May 16, 2022
Pancreatic Cancer: Team Science Propels New Ideas
- May 16, 2022
PROTAC Research Takes Aim at Drug Resistant Prostate Cancer
- May 16, 2022
BRCA Experts Rally to Research DNA Repair for Better Breast, Ovarian and Other Cancer Treatments
- May 16, 2022Source: Connecticut Health I-Team
Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Cancer
- May 16, 2022Source: The ASCO Post
PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors